1. Artificial Intelligence
Dr. Walker’s interest in AI has led him to using machine learning to predict varying health conditions including risk of autism spectrum disorder, renal anomalies, and preeclampsia. Dr. Walker and his teams’ investigations are demonstrating the possibilities of using AI as an invaluable tool for early screening strategies.

2. Gestational Diabetes
As a co-lead of the EAGER Pilot Trial, Dr. Walker is evaluating whether early induction of labour at 38 weeks improves outcomes for individuals with gestational diabetes mellitus to address ongoing debate about optimal delivery timing in this high-risk group. The pilot study aims to assess feasibility for a larger Canadian RCT.

3. Folic Acid Clinical Trial (FACT) Network
Serving as Co-PI, Dr. Walker helped launch the global Folic Acid Clinical Trial (FACT) Network collaboration of over 200 leading obstetricians, neonatologists, epidemiologists, and trialists testing high-dose folic acid (4 mg vs. 1 mg) for preventing preeclampsia and recurring hypertensive disorders.